Growth Metrics

Eli Lilly (LLY) Revenue Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 41.69%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 4.82%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 7.06%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 3.98%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 12.18%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 3.09%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -13.60%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.44%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 41.69%
Dec 31, 2025 38.24%
Sep 30, 2025 36.36%
Jun 30, 2025 33.85%
Mar 31, 2025 17.68%
Dec 31, 2024 19.15%
Sep 30, 2024 19.09%
Jun 30, 2024 18.81%
Mar 31, 2024 8.81%
Dec 31, 2023 7.93%
Sep 30, 2023 18.28%
Jun 30, 2023 14.76%
Mar 31, 2023 5.90%
Dec 31, 2022 6.10%
Sep 30, 2022 8.22%
Jun 30, 2022 4.80%
Mar 31, 2022 15.32%
Dec 31, 2021 12.37%
Sep 30, 2021 8.47%
Jun 30, 2021 6.47%
Mar 31, 2021 11.09%
Dec 31, 2020 6.49%
Sep 30, 2020 0.48%
Jun 30, 2020 -1.90%
Mar 31, 2020 3.87%
Dec 31, 2019 2.01%
Sep 30, 2019 1.80%
Jun 30, 2019 1.41%
Mar 31, 2019 1.53%
Dec 31, 2018 1.60%
Sep 30, 2018 2.28%
Jun 30, 2018 3.90%
Mar 31, 2018 2.24%
Dec 31, 2017 6.35%
Sep 30, 2017 5.09%
Jun 30, 2017 5.67%
Mar 31, 2017 3.74%
Dec 31, 2016 -0.28%
Sep 30, 2016 -3.47%
Jun 30, 2016 -3.04%
Mar 31, 2016 -4.59%
Dec 31, 2015 -3.37%
Sep 30, 2015 -3.05%
Jun 30, 2015 -3.85%
Mar 31, 2015 -6.06%
Dec 31, 2014 -5.39%
Sep 30, 2014 -7.44%
Jun 30, 2014 -7.58%
Mar 31, 2014 -7.09%
Dec 31, 2013 -2.08%
Sep 30, 2013 1.71%
Jun 30, 2013 1.99%
Mar 31, 2013 0.70%
Dec 31, 2012 0.13%
Sep 30, 2012 0.36%
Jun 30, 2012 1.90%
Mar 31, 2012 3.54%